The evolving use of measurable residual disease in chronic lymphocytic leukemia clinical trials. (2023)
Attributed to:
Evaluation of the CD4+ T cell tumour microenvironment of low grade B cell lymphoproliferative disorders
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.3389/fonc.2023.1130617
PubMed Identifier: 36910619
Publication URI: http://europepmc.org/abstract/MED/36910619
Type: Journal Article/Review
Volume: 13
Parent Publication: Frontiers in oncology
ISSN: 2234-943X